In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Food companies are capitalizing on the GLP-1 trend, offering high-protein, portion-controlled meals. But are they meeting ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

Are you somebody who is focused on trying to lose weight, but for some reason can’t? There could be several reasons for ...

SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a $271 million market cap player in the health and wellness sector with impressive 79% gross profit margins, today announced the successful ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

American host and television producer Oprah Winfrey recently shared her initial experience of taking the weight loss drug GLP ...

LifeVantage (LFVN) announced the completion of an international in vitro cell study that investigated the effects of its international ...